Different patterns of fibronectin and tenascin-C splice variants expression in primary and metastatic melanoma lesions
Open Access
- 7 June 2011
- journal article
- research article
- Published by Wiley in Experimental Dermatology
- Vol. 20 (8) , 685-688
Abstract
We have investigated the staining patterns of primary and metastatic melanoma lesions using F8, L19 and F16. These three clinical‐stage antibodies are currently being studied in clinical trials for the pharmacodelivery of cytokines or therapeutic radionuclides to neoplastic sites in patients with cancer. Frozen sections of 24 primary and 29 metastatic melanoma lesions were stained, using immunofluorescence procedures, with biotinylated preparations of the F8, L19 and F16 antibodies, which are specific to the alternatively spliced extra domain A and extra domain B domains of fibronectin and A1 domain of tenascin‐C, respectively. Blood vessels were costained using von Willebrand factor–specific antibodies. In primary cutaneous melanoma lesions, F16 and F8 (but not L19) strongly stained the basal lamina at the interface between epidermis and dermis, with a strikingly complementary pattern. By contrast, metastatic melanoma lesions displayed a strong and diffuse pattern of immunoreactivity with all three antibodies. It was found that the extracellular matrix in melanoma undergoes extensive remodelling during the transition from primary to metastatic lesions. The intense staining of metastatic melanoma lesions by the F8, L19 and F16 antibodies provides a strong rationale for the use of these antibodies and their derivatives for the treatment of melanoma patients and possibly for the personalized choice of the best performing antibody in individual patients.Keywords
This publication has 46 references indexed in Scilit:
- High response rate after intratumoral treatment with interleukin‐2Cancer, 2010
- Angiotensin II activates connective tissue growth factor and induces extracellular matrix changes involving Smad/activation and p38 mitogen‐activated protein kinase signalling pathways in human dermal fibroblastsExperimental Dermatology, 2009
- Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritisArthritis Research & Therapy, 2009
- 124I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of 131I-L19-SIP radioimmunotherapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2009
- Clinical Experience with α-Particle–Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6Journal of Nuclear Medicine, 2007
- The Extra-domain A of Fibronectin Is a Vascular Marker of Solid Tumors and MetastasesCancer Research, 2007
- Multiple cardiovascular defects caused by the absence of alternatively spliced segments of fibronectinDevelopmental Biology, 2007
- 131I Radioconjugated Antibodies for the Locoregional Radioimmunotherapy of High-grade Malignant Glioma: Phase I and II StudyActa Oncologica, 1999
- Transforming growth factor‐β regulates the splicing pattern of fibronectin messenger RNA precursorFEBS Letters, 1990
- Transforming growth factor β regulates the levels of different fibronectin isoforms in normal human cultured fibroblastsFEBS Letters, 1988